Kastan NR, Oak S, Liang R, Baxt L, Myers RW, Ginn J, Liverton N, Huggins DJ, Pichardo J, Paul M et al..  2022.  Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs.. Proc Natl Acad Sci U S A. 119(28):e2206113119.

Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX et al..  2022.  Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.. N Engl J Med. 386(8):735-743.

Knauf JA, Luckett KA, Chen K-Y, Voza F, Socci ND, Ghossein R, Fagin JA.  2018.  Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.. J Clin Invest. 128(9):4086-4097.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, Amadiume SC, Goncalves MD, Hodakoski C, Lundquist MR et al..  2018.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.. Nature. 560(7719):499-503.

Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TThi, Chaudhary N, Riely GJ, Li BT, Scott K et al..  2017.  An approach to suppress the evolution of resistance in BRAF-mutant cancer.. Nat Med. 23(8):929-937.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC et al..  2017.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.. Cancer Discov. 7(7):750-765.

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.  2017.  p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.. J Invest Dermatol. 137(10):2187-2196.

Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R et al..  2017.  A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.. Eur J Cancer. 83:229-236.

Xue Y, Lito P.  2017.  Predicting MEK Inhibitor Response in Lung Cancer: A Proper Signature Is Required.. Clin Cancer Res. 23(6):1365-1367.

Liang H, Zheng Q-L, Fang P, Zhang J, Zhang T, Liu W, Guo M, Robinson CL, Chen S-B, Chen X-P et al..  2017.  Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.. Sci Rep. 7:40361.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ et al..  2015.  CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.. Cancer Cell. 28(1):15-28.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney ASophia, Papalexi E et al..  2015.  JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.. Cancer Discov. 5(3):316-31.

McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T.  2014.  p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.. Proc Natl Acad Sci U S A. 111(16):E1600-9.

Dubrovsky L, Pankov D, Brea EJoseph, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.  2014.  A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.. Blood. 123(21):3296-304.